OptiNose — Q4 2021 Earnings Presentation
19 slides from OptiNose's earnings presentation, Mar 8, 2022
Slide 1: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n M a r c h 8 , 2 0 2 2 Exhibit 99.2
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this
Slide 3: Full Year 2021 Highlights
3 Full Year 2021 Highlights +27% XHANCE New Prescriptions Growth FY 2021/FY 2020 +52% XHANCE Net Revenue Growth FY 2021/FY 2020 $48.4 $73.7 2020 2021 ($M ) XHANCE Net Revenues $132M Full Year 2021 Operating Expenses (SG&A plus R&D) +28% XHANCE Prescriptions Growth FY 2021/FY 2020 +52%
Slide 4: XHANCE as First FDA-approved Drug Treatment for Chronic Sinusitis Creates Growth Opportunities
4 Successful Development of XHANCE as the First FDA-approved Drug Treatment for Chronic Sinusitis Creates Multiple New Opportunities for Growth Up to approximately 1 Million patients with nasal polyps (NP) are treated by specialty physicians who are the current focus of our sales deployment 1 Millio
Slide 5: Chronic Sinusitis Treatment Would Increase Opportunity and Address Prescribing Barriers
5 Successful Development of XHANCE as a Treatment for Chronic Sinusitis Would Increase Opportunity and Address Certain Barriers to Broader Prescribing that Exist Today Insurance Today, ~80% of commercial lives are in plans that cover XHANCE, but ~half require physicians to attest that they are pre
Slide 6: Objective evidence from large RCT of effect on inflammation in the sinuses
6 Objective evidence from large RCT of effect on inflammation deep inside the sinuses would be available for XHANCE for the first time Representative APOV Improvement in ReOpen1 in Patient Treated with XHANCE 186 µg BID 6.4% Improvement Week 24Baseline Images reflect individual results and results a
Slide 7: Q4 2021 Performance
optinose_ ——— Q4 2021 Performance
Slide 8: Key Takeaways and Q4 2021 Highlights
8 Key Takeaways and Q4 2021 Highlights Consistent Commercial Execution Driving Q4 2021 Growth FY 2022 Revenue Guidance Implies Y/Y Growth of at least 22% Positive Top-Line Results from ReOpen1 Reported in 1Q2022 +44% XHANCE Net Revenue Growth Q4 2021/Q4 2020 $240 XHANCE Net Revenue per TRx in Q4 202
Slide 9: XHANCE New and Total Prescriptions
9 XHANCE New and Total Prescriptions XHANCE New Prescriptions increased 21% and Total Prescriptions increased 27% from Q4 2020 to Q4 2021 Estimated based on monthly prescription data from third parties and XHANCE preferred pharmacy network. The Market on this slide is defined as the sum of all intra
Slide 10: XHANCE Market Share & Prescribers by Prescribing Frequency
10 XHANCE Market Share & Prescribers by Prescribing Frequency The Market on this slide is defined as the sum of all intranasal steroid prescriptions written by physicians in the XHANCE target physician audience of approximately 18,000 physicians. Estimated based on monthly prescription data from thi
Slide 11: Q4 and Full Year 2021 Financial Update
Q4 and Full Year 2021 Financial Update
Slide 12: Financial Review – XHANCE Net Revenue
12 $48.4 $73.7 FY 2020 FY 2021 Financial Review – XHANCE Net Revenue XHANCE Net Revenue Increased 44% from Q4 2020 to Q4 2021 and 52% for Full Year 2021 $15.6 $22.5 Q4 '20 Q4 '21 ($M) +44% Net Revenue Net Revenue +52% ($M)
Slide 13: Financial Review – XHANCE Average Net Revenue per Prescription
13 $211 $240 Q4 '20 Q4 '21 Financial Review – XHANCE Average Net Revenue per Prescription XHANCE Average Net Revenue per TRx Increased from $211 to $240 from Q4 2020 to Q4 2021 and from $185 to $219 for Full Year 2021 $185 $219 FY 2020 FY 2021 +19% Average Net Revenue per TRx Average Net Revenue per
Slide 14: Full Year 2022 Financial Guidance
14 Full Year 2022 Financial Guidance XHANCE Net Revenue ‒ Expected to be at least $90 million XHANCE Average Net Revenue per Prescription ‒ FY 2022 expected to exceed $210 ‒ Q1 2022 expected Operating Expense (GAAP) ‒ Expected to be between $135 – $140 million; approximately $10 million of whi
Slide 15: Additional Phase 3b Clinical Trial Data Expected in Q2 22
15 Additional Phase 3b Clinical Trial Data Expected in Q2 2022 Recruitment Completed July 2021 Recruitment Completed October 2021 Top-line results expected in Q1 2022 Top-line results expected in Q2 2022
Slide 16: Closing Remarks
optinose_ ——— Closing Remarks
Slide 17: Key Takeaways and Q4 2021 Highlights
17 Key Takeaways and Q4 2021 Highlights Consistent Commercial Execution Driving Q4 2021 Growth FY 2022 Revenue Guidance Implies Y/Y Growth of at least 22% Positive Top-Line Results from ReOpen1 Reported in 1Q2022 +44% XHANCE Net Revenue Growth Q4 2021/Q4 2020 $240 XHANCE Net Revenue per TRx in Q4 20
Slide 18: Investor Relations – Optinose Investor Contact
18 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Development 267-521-0531 Investors@optinose.com At 31 December 2021: – $111 million in cash – Long-term debt: $130 million – 82.2 million common shares o/s – 12.4 million options, warra
Slide 19: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n M a r c h 8 , 2 0 2 2